32.27

1.22% -0.473

Ideaya Biosciences Inc (IDYA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$32.74

Offen:

$33.26

24-Stunden-Volumen:

274.73K

Relative Volume:

0.31

Marktkapitalisierung:

$2.84B

Einnahmen:

$218.71M

Nettoeinkommen (Verlust:

$-113.70M

KGV:

-24.76

EPS:

-1.3034

Netto-Cashflow:

$-73.47M

1W Leistung:

+2.83%

1M Leistung:

-2.56%

6M Leistung:

+17.64%

1J Leistung:

+119.85%

1-Tages-Spanne:

$32.21

$33.65

1-Wochen-Bereich:

$31.77

$34.47

52-Wochen-Spanne:

$13.45

$39.28

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Firmenname

Ideaya Biosciences Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (624)

Telefon

650-443-6209

Adresse

5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA

Mitarbeiter

145

Twitter

Nächster Verdiensttermin

2026-02-13

Neueste SEC-Einreichungen

IDYA's Discussions on Twitter

Compare IDYA vs VRTX, REGN, ARGX, ALNY, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
IDYA Ideaya Biosciences Inc	32.30	2.88B	218.71M	-113.70M	-73.47M	-1.3034
VRTX Vertex Pharmaceuticals Inc	433.58	111.45B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	762.40	80.54B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	747.05	46.32B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	330.89	42.29B	3.71B	313.75M	465.38M	2.2571
INSM Insmed Inc	163.74	35.01B	606.42M	-1.28B	-997.58M	-6.403

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-07	Fortgesetzt	UBS	Buy
2025-11-24	Eingeleitet	Truist	Buy
2025-09-18	Eingeleitet	Guggenheim	Buy
2025-09-04	Eingeleitet	Barclays	Overweight
2025-09-04	Eingeleitet	Citizens JMP	Mkt Outperform
2025-07-22	Eingeleitet	TD Cowen	Buy
2025-07-10	Fortgesetzt	Goldman	Neutral
2025-06-26	Eingeleitet	Wells Fargo	Overweight
2024-11-18	Eingeleitet	Stephens	Overweight
2024-11-05	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-10-24	Eingeleitet	UBS	Buy
2024-10-15	Eingeleitet	Cantor Fitzgerald	Overweight
2024-07-08	Eingeleitet	Mizuho	Outperform
2024-03-08	Eingeleitet	BTIG Research	Buy
2023-08-08	Eingeleitet	SVB Securities	Outperform
2023-05-24	Eingeleitet	Goldman	Buy
2023-04-24	Hochstufung	Stifel	Hold → Buy
2023-03-23	Eingeleitet	Berenberg	Buy
2023-02-28	Eingeleitet	RBC Capital Mkts	Outperform
2022-12-28	Eingeleitet	CapitalOne	Overweight
2022-10-27	Eingeleitet	Citigroup	Buy
2022-08-15	Herabstufung	Stifel	Buy → Hold
2022-07-18	Fortgesetzt	Oppenheimer	Outperform
2022-03-10	Hochstufung	Stifel	Hold → Buy
2021-09-23	Eingeleitet	Stifel	Hold
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-03-11	Eingeleitet	Guggenheim	Buy
2020-10-07	Eingeleitet	Wedbush	Outperform
2020-09-01	Eingeleitet	Northland Capital	Outperform
2020-07-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-06-17	Bestätigt	H.C. Wainwright	Buy
2020-04-06	Eingeleitet	H.C. Wainwright	Buy
2020-03-13	Eingeleitet	ROTH Capital	Buy
2019-10-17	Eingeleitet	Oppenheimer	Outperform
2019-09-10	Eingeleitet	Robert W. Baird	Outperform
2019-06-17	Eingeleitet	Citigroup	Buy
2019-06-17	Eingeleitet	JP Morgan	Neutral
2019-06-17	Eingeleitet	Jefferies	Buy

Alle ansehen

Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten

06:50 AM

Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada

06:50 AM

06:46 AM

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView

06:46 AM

06:00 AM

Breast to lung cancers: IDEAYA puts IDE574 into human testing - Stock Titan

06:00 AM

Apr 04, 2026

IDYA PE Ratio & Valuation, Is IDYA Overvalued - Intellectia AI

Apr 04, 2026

Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - Yahoo Finance

Apr 04, 2026

Apr 03, 2026

A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - Yahoo Finance

Apr 03, 2026